Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13492517 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL20124235 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL2409907 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL16199449 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL12824691 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL15508609 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL15599086 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL14400257 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL21255728 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 | |
| SCHEMBL20124266 | 1.00 | LMNA (0.45) | LMNAMAPK1HTTNOS2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001594-B2 | Heterocyclic modulators of HIF activity for treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-05-11 | — | — | US | disclosed |
| US-20190270753-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | UNIV TEXAS (US) | 2019-09-05 | — | — | US | disclosed |
| EP-2888255-B1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | UNIV TEXAS (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2543991-B1 | URACIL-SPECIFIC FLUORESCENCE DETECTION REACTION AND METHOD FOR EXAMINING DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY | UNIV NAGASAKI (JP) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270753-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | LMNA 3216/4885MAPK1 1720/4885HTT 1475/4885 |
| US-11001594-B2 | Heterocyclic modulators of HIF activity for treatment of disease | HIF1AN, HIF1A, EGLN3 | LMNA 3216/4885MAPK1 1720/4885HTT 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.